Find a Drug
Advanced Search

Professional

Zofran Injection

Clinical Pharmacology
font size

Clinical Pharmacology

Adult Studies: Adult surgical patients who received ondansetron immediately before the induction of general balanced anesthesia (barbiturate: thiopental, methohexital, or thiamylal; opioid: alfentanil or fentanyl; nitrous oxide; neuromuscular blockade: succinylcholine/curare and/or vecuronium or atracurium; and supplemental isoflurane) were evaluated in two double-blind US studies involving 554 patients. ZOFRAN Injection (4 mg) I.V. given over 2 to 5 minutes was significantly more effective than placebo. The results of these studies are summarized in Table 8.

Table 8. Prevention of Postoperative Nausea and Vomiting in Adult Patients


  Ondansetron
4 mg I.V.
Placebo P Value
Study 1      
Emetic episodes:      
Number of patients 136 139  
Treatment response over 24-h postoperative period      
  0 Emetic episodes 103 (76%) 64 (46%) < 0.001
  1 Emetic episode 13 (10%) 17 (12%)  
   More than 1 emetic episode/rescued 20 (15%) 58 (42%)  
Nausea assessments:      
Number of patients 134 136  
No nausea over 24-h postoperative period 56 (42%) 39 (29%)  
Study 2      
Emetic episodes:      
Number of patients 136 143  
Treatment response over 24-h postoperative period      
  0 Emetic episodes 85 (63%) 63 (44%) 0.002
  1 Emetic episode 16 (12%) 29 (20%)  
  More than 1 emetic episode/rescued 35 (26%) 51 (36%)  
Nausea assessments:      
Number of patients 125 133  
No nausea over 24-h postoperative period 48 (38%) 42 (32%)  

The study populations in Table 8 consisted mainly of females undergoing laparoscopic procedures.

In a placebo-controlled study conducted in 468 males undergoing outpatient procedures, a single 4-mg I.V. ondansetron dose prevented postoperative vomiting over a 24-hour study period in 79% of males receiving drug compared to 63% of males receiving placebo (P < 0.001).

Two other placebo-controlled studies were conducted in 2,792 patients undergoing major abdominal or gynecological surgeries to evaluate a single 4-mg or 8-mg I.V. ondansetron dose for prevention of postoperative nausea and vomiting over a 24-hour study period. At the 4-mg dosage, 59% of patients receiving ondansetron versus 45% receiving placebo in the first study (P < 0.001) and 41% of patients receiving ondansetron versus 30% receiving placebo in the second study (P=0.001) experienced no emetic episodes. No additional benefit was observed in patients who received I.V. ondansetron 8 mg compared to patients who received I.V. ondansetron 4 mg.

Brand Name: Zofran Injection
Generic Name: Ondansetron Hydrochloride Injection
Bookmark this page:

Cancer

Get the latest treatment options.

WebMD Symptom Checker - Start Here Ringworm Slideshow: Watch and Learn

Cancer and ExerciseCancer and Exercise
Resting to conserve energy may not be the best remedy for fatigue during radiation therapy. See more WebMD Videos »